{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:07Z","timestamp":1740106927261,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00277-022-04940-6","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T13:02:52Z","timestamp":1659790972000},"page":"2551-2552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate"],"prefix":"10.1007","volume":"101","author":[{"given":"Kazutoshi","family":"Ebisawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Masamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-2422","authenticated-orcid":false,"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"key":"4940_CR1","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","volume":"381","author":"A Tefferi","year":"2019","unstructured":"Tefferi A, Pardanani A (2019) Essential thrombocythemia. N Engl J Med 381:2135\u20132144","journal-title":"N Engl J Med"},{"key":"4940_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.579221","volume":"10","author":"Z Wan","year":"2020","unstructured":"Wan Z, Han B (2020) Comparison and implications of mutational profiles of myelodysplastic syndromes, myeloproliferative neoplasms, and myelodysplastic\/myeloproliferative neoplasms: a meta-analysis. Front Oncol 10:579221","journal-title":"Front Oncol"},{"key":"4940_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12185-009-0345-y","volume":"90","author":"RH Nussenzveig","year":"2009","unstructured":"Nussenzveig RH, Cortes J, Sever M et al (2009) Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol 90:58\u201363","journal-title":"Int J Hematol"},{"key":"4940_CR4","first-page":"129","volume":"1","author":"RA Mesa","year":"2007","unstructured":"Mesa RA (2007) Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders. Biologics 1:129\u2013138","journal-title":"Biologics"},{"key":"4940_CR5","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/cncr.20211","volume":"100","author":"J Cortes","year":"2004","unstructured":"Cortes J, Kantarjian H (2004) Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. Cancer 100:2064\u20132078","journal-title":"Cancer"},{"key":"4940_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/COC.0000000000000023","volume":"39","author":"MR Green","year":"2016","unstructured":"Green MR, Newton MD, Fancher KM (2016) Off-target effects of BCR-ABL and JAK2 inhibitors. Am J Clin Oncol 39:76\u201384","journal-title":"Am J Clin Oncol"},{"key":"4940_CR7","first-page":"526","volume":"24","author":"LX Zhou","year":"2016","unstructured":"Zhou LX, Liang EY, Ye JY, Yang M (2016) Role of PDGF\/PDGFR pathway in essential thrombocythemia and its action mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi 24:526\u2013530","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"4940_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41408-017-0041-8","volume":"8","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Vannucchi AM, Barbui T (2018) Essential thrombocythemia treatment algorithm 2018. Blood Cancer J 8:2","journal-title":"Blood Cancer J"},{"key":"4940_CR9","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"S Cortelazzo","year":"1995","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M et al (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132\u20131136","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04940-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04940-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04940-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T05:02:45Z","timestamp":1665118965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04940-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["4940"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04940-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"9 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Full informed consent was obtained from the patient in this report for the treatment. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent to publish was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Dr. YM received lecture fees from Bristol Myers Squibb and Takeda Pharmaceutical Co.Ltd. Dr. MK received lecture fees from Bristol Myers Squibb and lecture fees and scholarship donations from Takeda Pharmaceutical Co., Ltd. The other authors (Drs. KE, KY) declared that they had no relevant financial relationships to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflit of interest"}}]}}